Search clinical trials for: Avelumab

Total 302 results

Institut Paoli-Calmettes

Not yet recruiting

Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer (PREVERT)

Non-muscle-invasive Bladder Cancer
Kartos Therapeutics, Inc.

Recruiting

Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

Merkel Cell Carcinoma

United States, Netherlands, Korea, Republic of, France, Germany, Spain, Canada, Italy, Australia, Brazil
University Health Network, Toronto

Recruiting

A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy

Metastatic Cancer | Advanced Cancer | Penile Cancer

Canada
University Hospital, Bordeaux

Terminated

First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma (GCISAVE)

Bladder Carcinoma

France
University of Campania "Luigi Vanvitelli"

Recruiting

CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

Metastatic Colorectal Cancer

Italy
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Active, not recruiting

Avelumab With Radiotherapy in Patients With Leptomeningeal Disease

Leptomeningeal Metastases | Leptomeningeal Disease

United States
Royal Marsden NHS Foundation Trust
Merck KGaA, Darmstadt, Germany; University of Oxford; University of Surrey

Terminated

Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer (POLEM)

Microsatellite Instability | Stage III Colon Cancer | POLE Exonuclease Mutant Colon Cancer

United Kingdom
Pfizer

Terminated

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

Ovarian Cancer

Korea, Republic of, United States, Singapore, Taiwan, Japan, Italy, Australia, Belgium, Ireland, Russian Federation
Jules Bordet Institute

Recruiting

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Melanoma | Renal Cell Carcinoma | Breast Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Non Small Cell Lung Cancer | Mesothelioma, Malignant | Bladder Cancer | Gastrointestinal Cancer | Merkel Cell Carcinoma | Non-melanoma Skin Cancer | MSI-H Colorectal Cancer

Belgium
Monika Joshi, MD
Pfizer; Eisai Inc.; Big Ten Cancer Research Consortium

Terminated

A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients

Metastatic Urothelial Cell Cancer

United States
National Cancer Institute (NCI)

Terminated

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

Clear-Cell Renal Carcinoma

United States
EMD Serono Research & Development Institute, Inc.

Completed

Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)

Carcinoma, Merkel Cell

United States, Spain, Australia, Italy, Germany, France, Japan
Washington University School of Medicine
Pfizer

Terminated

Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma

Meningioma | Meningioma, Adult

United States
Associació per a la Recerca Oncologica, Spain
Pivotal S.L.; Merck, S.L., Spain

Completed

Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma (INDUCOMAIN)

Metastatic Urothelial Cancer

Spain
Melanoma and Skin Cancer Trials Limited

Recruiting

Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma (I-MAT)

Neuroendocrine Tumors | Merkel Cell Carcinoma | Merkel Cell Carcinoma, Stage I | Merkel Cell Carcinoma, Stage II | Merkel Cell Carcinoma, Stage III | Carcinoma Neuroendocrine Skin

Australia, New Zealand
NYU Langone Health
EMD Serono

Completed

Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma

Glioblastoma

United States
Johannes Gutenberg University Mainz
Merck KGaA, Darmstadt, Germany

Completed

Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy (AveNEC)

Cancer

Germany
Icahn School of Medicine at Mount Sinai

Completed

Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma

Glioblastoma | GBM

United States
Institut Bergonié
Merck Sharp & Dohme LLC; National Cancer Institute, France; Transgene; Fondation...

Recruiting

A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (METROmaJX)

Breast Cancer | Soft-tissue Sarcoma | Solid Tumors

France
AdventHealth
Jazz Pharmaceuticals

Recruiting

Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

Metastatic Cancer | Urothelial Carcinoma

United States
Pfizer
EMD Serono; Astellas Pharma Inc; Nektar Therapeutics

Terminated

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Metastatic Castration Resistant Prostate Cancer (mCRPC)

Spain, United States, Poland, Belgium
University of Oklahoma
EMD Serono

Completed

Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer (OU-SCC-ABC)

Bladder Cancer

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Solid Tumors

United States, Korea, Republic of, Taiwan, France, United Kingdom, Belgium, Czechia, Germany, Poland
National Cancer Institute (NCI)

Completed

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

Mycosis Fungoides | Sezary Syndrome | Anaplastic Large Cell Lymphoma | Peripheral T-cell Lymphoma NOS

United States
Pfizer

Active, not recruiting

A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

Renal Cell Cancer

United States, Hungary, Spain, United Kingdom, Belgium, Korea, Republic of, Canada, Israel, Denmark, Australia, Italy, Japan, France, Austria, New Zealand, Romania, Russian Federation, Netherlands, Germany, Mexico, Sweden
Vaximm GmbH
Pfizer; Merck KGaA, Darmstadt, Germany

Active, not recruiting

VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

Recurrent Glioblastoma

Germany
Versailles Hospital

Recruiting

Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) (ACTIW)

Leukemia, Myeloid, Chronic-Phase

France
PH Research, S.L.

Terminated

A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma

Spain
Bristol-Myers Squibb

Completed

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma

United States, France, Spain, Germany
Jodi Layton, MD
EMD Serono

Terminated

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Metastatic Castration-resistant Prostate Cancer

United States
Pfizer

Terminated

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

Advanced Cancer

United States, Canada, United Kingdom, Taiwan, Australia, France, Japan, Poland
Jules Bordet Institute
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial) (AURA)

Non-metastatic Muscle Invasive Bladder Cancer

France, Belgium
Gilead Sciences
Merck KGaA, Darmstadt, Germany

Completed

Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

Ovarian Cancer

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Phase I/II Study of Avelumab in Pediatric Cancer Subjects

Lymphoma | Refractory or Relapsed Solid Tumors

Korea, Republic of, United States, Canada, Belgium, Denmark
ImmunityBio, Inc.

Active, not recruiting

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability | Mismatch Repair Deficiency

United States
St. Jude Children's Research Hospital
Pfizer; Gateway for Cancer Research

Completed

A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma

Osteosarcoma

United States
Pfizer

Terminated

Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)

Hodgkins Lymphoma

United Kingdom, United States, Italy
Pfizer

Withdrawn

Axitinib Therapy Management Study

Renal Cell Carcinoma

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Central Nervous System Tumors

Korea, Republic of, United States, Canada, Germany, France
NKGen Biotech, Inc.

Active, not recruiting

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

Metastatic Cancer | Advanced Solid Tumor | Advanced Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer | Unresectable Carcinoma

United States
Dana-Farber Cancer Institute
Pfizer

Active, not recruiting

RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA

Follicular Lymphoma

United States
Hospital of Macerata

Recruiting

International Multicentric Study ARON-1

Metastatic Renal Cell Carcinoma (mRCC)

Italy
Memorial Sloan Kettering Cancer Center
Pfizer

Withdrawn

Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | Minimal Residual Disease

United States
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

Solid Tumors | Peritoneal Carcinomatosis

Germany
Chinese University of Hong Kong

Active, not recruiting

NPC - AXEL Study : Axitinib-Avelumab

Recurrent or Metastatic NPC

Hong Kong
Maria Sklodowska-Curie National Research Institute...

Recruiting

A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy (AXAGIST)

Gastrointestinal Stromal Tumors

Poland
The Netherlands Cancer Institute
Pfizer

Recruiting

Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC

Renal Cell Carcinoma

Netherlands
University of Texas Southwestern Medical Center
Pfizer

Terminated

Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Pfizer

Terminated

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Australia, Japan
Johns Hopkins University

Completed

Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors

Cutaneous Toxicity From ICI Therapy

United States

Search clinical trials for: Avelumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations